Skip to Main Content
DownloadHi-Res Photo

Zenta Walther, MD, PhD

Associate Professor of Pathology; Clinical Director, YNHH Tumor Profiling Laboratory; Director, Molecular Genetic Pathology Fellowship Program

Contact Information

Zenta Walther, MD, PhD

Office Location

Mailing Address

  • 310 Cedar Street

    PO Box 208023

    New Haven, CT 06520-8023

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Coauthors

Selected Publications

  • Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testing.Hafez N, Walther Z, Eder JP, Sklar JL, Gettinger SN, Finberg KE, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testing. The Lancet. Oncology 2020, 21: 343-344. PMID: 32950226, DOI: 10.1016/S1470-2045(20)30010-3.
  • The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.Truini A, Starrett JH, Stewart TF, Ashtekar KD, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K. The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 6382-6391. PMID: 31182434, PMCID: PMC6825535, DOI: 10.1158/1078-0432.CCR-19-0780.
  • Endogenous development of Cystoisospora belli in intestinal and biliary epithelium of humans.Dubey JP, Evason KJ, Walther Z. Endogenous development of Cystoisospora belli in intestinal and biliary epithelium of humans. Parasitology 2019, 146: 865-872. PMID: 30859916, DOI: 10.1017/S003118201900012X.
  • Introduction to the Yale Precision Medicine Tumor Board.Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB. Introduction to the Yale Precision Medicine Tumor Board. The Lancet. Oncology 2018, 19: 19-20. PMID: 29304351, DOI: 10.1016/S1470-2045(17)30919-1.
  • Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes.Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. The Lancet. Oncology 2018, 19: 23-24. PMID: 29304353, DOI: 10.1016/S1470-2045(17)30916-6.
  • Yale Cancer Center Precision Medicine Tumor Board: one tumour, multiple targets.Stewart T, Finberg K, Walther Z, Sklar JL, Hafez N, Eder JP, Anderson K, Wilson F, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: one tumour, multiple targets. The Lancet. Oncology 2018, 19: 1567-1568. PMID: 32956641, DOI: 10.1016/S1470-2045(18)30759-9.
  • Congenital Extrahepatic Portosystemic Shunt (Abernethy Malformation Type Ib) With Associated Hepatocellular Carcinoma: Case Report and Literature Review.Benedict M, Rodriguez-Davalos M, Emre S, Walther Z, Morotti R. Congenital Extrahepatic Portosystemic Shunt (Abernethy Malformation Type Ib) With Associated Hepatocellular Carcinoma: Case Report and Literature Review. Pediatric And Developmental Pathology : The Official Journal Of The Society For Pediatric Pathology And The Paediatric Pathology Society 2017, 20: 354-362. PMID: 28727971, DOI: 10.1177/1093526616686458.
  • Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.Lih CJ, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, Finberg KE, Canosa S, Robinson H, Raymond A, Le LP, McShane LM, Polley EC, Conley BA, Doroshow JH, Iafrate AJ, Sklar JL, Hamilton SR, Williams PM. Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. The Journal Of Molecular Diagnostics : JMD 2017, 19: 313-327. PMID: 28188106, PMCID: PMC5397672, DOI: 10.1016/j.jmoldx.2016.10.007.
  • Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.de Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger S, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gómez-Román J, García-Castaño A, Gong Y, Ladanyi M, Varmus H, Bernards R, Smit EF, Politi K, Downward J. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discovery 2014, 4: 606-19. PMID: 24535670, PMCID: PMC4011693, DOI: 10.1158/2159-8290.CD-13-0741.
  • Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Reports 2014, 7: 999-1008. PMID: 24813888, PMCID: PMC4074596, DOI: 10.1016/j.celrep.2014.04.014.
  • MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice.Hoshi N, Schenten D, Nish SA, Walther Z, Gagliani N, Flavell RA, Reizis B, Shen Z, Fox JG, Iwasaki A, Medzhitov R. MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice. Nature Communications 2012, 3: 1120. PMID: 23047678, PMCID: PMC3521499, DOI: 10.1038/ncomms2113.
  • Mitochondrial genome instability and ROS enhance intestinal tumorigenesis in APC(Min/+) mice.Woo DK, Green PD, Santos JH, D'Souza AD, Walther Z, Martin WD, Christian BE, Chandel NS, Shadel GS. Mitochondrial genome instability and ROS enhance intestinal tumorigenesis in APC(Min/+) mice. The American Journal Of Pathology 2012, 180: 24-31. PMID: 22056359, PMCID: PMC3338350, DOI: 10.1016/j.ajpath.2011.10.003.
  • Molecular tumor profiling for prediction of response to anticancer therapies.Walther Z, Sklar J. Molecular tumor profiling for prediction of response to anticancer therapies. Cancer Journal (Sudbury, Mass.) 2011, 17: 71-9. PMID: 21427550, DOI: 10.1097/PPO.0b013e318212dd6d.
  • Molecular pathology of hepatic neoplasms: classification and clinical significance.Walther Z, Jain D. Molecular pathology of hepatic neoplasms: classification and clinical significance. Pathology Research International 2011, 2011: 403929. PMID: 21559202, PMCID: PMC3090128, DOI: 10.4061/2011/403929.
  • CASK deletion in intestinal epithelia causes mislocalization of LIN7C and the DLG1/Scrib polarity complex without affecting cell polarity.Lozovatsky L, Abayasekara N, Piawah S, Walther Z. CASK deletion in intestinal epithelia causes mislocalization of LIN7C and the DLG1/Scrib polarity complex without affecting cell polarity. Molecular Biology Of The Cell 2009, 20: 4489-99. PMID: 19726564, PMCID: PMC2770937, DOI: 10.1091/mbc.E09-04-0280.
  • Isospora cholangiopathy: case study with histologic characterization and molecular confirmation.Walther Z, Topazian MD. Isospora cholangiopathy: case study with histologic characterization and molecular confirmation. Human Pathology 2009, 40: 1342-6. PMID: 19447468, DOI: 10.1016/j.humpath.2009.01.020.
  • A PDZ-binding motif controls basolateral targeting of syndecan-1 along the biosynthetic pathway in polarized epithelial cells.Maday S, Anderson E, Chang HC, Shorter J, Satoh A, Sfakianos J, Fölsch H, Anderson JM, Walther Z, Mellman I. A PDZ-binding motif controls basolateral targeting of syndecan-1 along the biosynthetic pathway in polarized epithelial cells. Traffic (Copenhagen, Denmark) 2008, 9: 1915-24. PMID: 18764819, PMCID: PMC2820280, DOI: 10.1111/j.1600-0854.2008.00805.x.
  • COX-2 and angiogenesis in gastric cancer.Walther Z. COX-2 and angiogenesis in gastric cancer. Journal Of Clinical Gastroenterology 2003, 37: 4-6. PMID: 12811200, DOI: 10.1097/00004836-200307000-00003.
  • hCASK and hDlg associate in epithelia, and their src homology 3 and guanylate kinase domains participate in both intramolecular and intermolecular interactions.Nix SL, Chishti AH, Anderson JM, Walther Z. hCASK and hDlg associate in epithelia, and their src homology 3 and guanylate kinase domains participate in both intramolecular and intermolecular interactions. The Journal Of Biological Chemistry 2000, 275: 41192-200. PMID: 10993877, DOI: 10.1074/jbc.M002078200.

Clinical Trials

ConditionsStudy Title
LungDetermining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer
Edit Profile